abstract |
An aqueous ophthalmic formulation is disclosed, which comprises: (a) at least one cyclosporine having solubility in the formulation above about 28 microgram/mL; (b) a surface active agent which is a polysorbate; and (c) a nonionic tonicity agent which is a low molecular weight polyethylene glycol (PEG), which may be selected from the group consisting of PEG 200, PEG 300, PEG 400, and PEG 600; andwherein said aqueous formulation may further comprise: (d) one or more buffering agents and wherein the pH of the ophthalmic formulation is stable for at least 3 months; and wherein said ophthalmic formulation may further comprises: (e) at least one corticosteroid. |